UCHealth and CU School of Medicine researchers are recruiting participants for another COVID-19 vaccine trial, Phase 3 of Novavax (NVX-CoV2373), the organization said in a release on January 11. 

Novavax is the third COVID-19 vaccine trial UC Health is conducting, however it will be held at the Anschutz Medical Campus in Denver and will be focused on at-risk populations based on ethnicity, age and health conditions. The two doses are administered 21 days apart, and volunteer participants will be monitored for two years.

'The emphasis of the Novavax phase 3 trial is on demonstrating safety and effectiveness of the vaccine in people who are most at-risk for contracting and becoming ill from COVID-19,' the release said. 'UCHealth will also recruit individuals in higher-risk groups including Black, Hispanic, American Indian and Alaska Native study participants as well as those with certain health conditions, including those over 65 years old and people suffering from diabetes, obesity, heart disease, lung disease, or chronic kidney disease.'

UC Health says it will contact potential candidates who meet the criteria through their UC Health patient portal. In Northern Colorado, UC Health is currently participating in trials of the AstraZeneca COVID-19 vaccine only.

Enter your number to get our free mobile app

10 Northern Colorado Events We Can't Wait For in 2021